Editor' summary: A paradigm shift in castration-resistant prostate cancer management

Affiliations

¹ Division of Urology, Ospedale Sant'Andrea, Sapienza University of Rome, Roma, Italy. cosimodenunzio@virgilio.it.
² Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
³ Department of Urology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
⁴ City of Hope National Cancer Center, Duarte, CA, USA.

Editorial

Cosimo De Nunzio et al. Prostate Cancer Prostatic Dis. 2022 Apr.

. 2022 Apr;25(4):601-603.

doi: 10.1038/s41391-022-00574-x. Epub 2022 Jul 15.

¹ Division of Urology, Ospedale Sant'Andrea, Sapienza University of Rome, Roma, Italy. cosimodenunzio@virgilio.it.
² Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
³ Department of Urology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
⁴ City of Hope National Cancer Center, Duarte, CA, USA.

No abstract available

References

1. De Nunzio C, Presicce F, Giacinti S, Bassanelli M, Tubaro A. Castration-resistance prostate cancer: what is in the pipeline? Minerva Urol Nefrol. 2018;70:22–41.
1. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–82. - DOI
1. Mori K, Miura N, Mostafaei H, Quhal F, Sari Motlagh R, Pradere B, et al. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2020;23:539–48. - DOI
1. Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015;18:122–7. - DOI
1. Shore N, Higano CS, George DJ, Sternberg CN, Saad F, Tombal B, et al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:680–8. - DOI